<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Rituximab, a monoclonal antibody, is effective in CD20-positive B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and is now widely used either as a single agent or in combination with chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>The antibody's toxicity is generally mild and transient </plain></SENT>
<SENT sid="2" pm="."><plain>There are reports of protracted <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in patients treated with rituximab </plain></SENT>
<SENT sid="3" pm="."><plain>CASE REPORT: We report on a patient with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treated with the hyper-CVAD chemotherapy regimen combined with rituximab </plain></SENT>
<SENT sid="4" pm="."><plain>Four weeks after the five months' treatment marked <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:e sem="disease" ids="C0086438" disease_type="Disease or Syndrome" abbrv="">hypogammaglobulinaemia</z:e> occurred and persisted for one year </plain></SENT>
<SENT sid="5" pm="."><plain>Both laboratory findings were not associated with severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in our patient </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Delayed-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> is a newly recognised toxicity of rituximab treatment which may last up to one year and be complicated by serious <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
</text></document>